The pooled pCR rate for EGFR inhibitors was 15% (95% confidence interval (95% CI), 11-20%; I<sup>2</sup> = 55.2%); the pooled estimates of Grade 3/4 diarrhea, Grade 3/4 hand-foot syndrome, Grade 3/4 acneiform rash were 17% (95% CI, 4-34%; I<sup>2</sup> = 93.3%), 2% (95% CI, 0-5%; I<sup>2</sup> = 13.7%), and 15% (95% CI, 9-22%; I<sup>2</sup> = 65.4%), respectively.<h4>Conclusion</h4>The addition of EGFR inhibitors in the nCRT for KRAS-wild type LARC patients provides comparable efficacy and acceptable safety. Here, KRAS is linked to Hand-foot syndrome.